Blood Collection Market Market Analysis

Product Type (Venous, Capillary)

In blood collection market, venous segment is predicted to dominate revenue share of over 80.5% by 2037. The rising number of surgical procedures and the growing need for medical equipment for diagnosis and detection is fuelling the growth of the segment. Venous blood samples are the gold standard for a wide range of diagnostic tests, leading to sustained demand. Moreover, manufacturers are investing heavily in the development of devices with enhanced safety such as safety needles and blood collection sets to mitigate contamination risks. Venous blood collection products are more reliable and consistent, which is driving their demand for accurate diagnostic results and long-term studies.

Method (Manual Blood Collection, Automated Blood Collection)

By 2037, manual blood collection segment is projected to account for blood collection market share of around 70.5%, owing to its cost-effectiveness and extensive use by hospitals, individual clinical laboratories, and pathology laboratories. Manual blood collection systems are less expensive compared to automated ones, which makes them accessible to a wide range of healthcare facilities.

Additionally, manual methods can be used in low-resource environments. For instance, according to the WHO, in 2021, 4.5 billion people worldwide lacked complete access to basic healthcare services, highlighting the need for simpler blood collection methods.

Application (Diagnostics, Treatment, Research)

Diagnostics segment is anticipated to capture blood collection market share of over 68.5% by 2037. The rising importance of preventive healthcare on regular blood testing for early detection of diseases is augmenting the demand for diagnostic blood collection products. This trend is expected to maintain its dominance as the healthcare sector expands, driving the reliance on blood-based diagnostics.

Moreover, companies specializing in diagnostic technologies often partner with hospitals and research institutions to develop and validate innovative tests for early cancer detection. These collaborations facilitate access to clinical data and patient samples, significantly boosting the demand for diagnostic testing. For instance, in 2023, Providence, a non-profit health system serving the Western U.S., and GRAIL, LLC, a healthcare company, announced the expansion of their partnership to include multi-cancer early detection screening as part of clinical care for eligible individuals across Providence health system. Through the collaboration, eligible patients at Providence's 52 hospitals and 900 clinics in seven states will have access to GRAIL's Galleri multi-cancer early detection (MCED) test as part of a broad range of health services.

Our in-depth analysis of the blood collection market includes the following segments: